Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
Express Scripts to add Zepbound to National Preferred Formulary
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
Venus Remedies is supplying the drug to many countries like Colombia, Thailand, Tanzania, Morocco, Myanmar, Indonesia, Saudi Arabia, Malaysia, Zimbabwe, Sri Lanka, Pakistan, Kenya, and Botswana
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
The CAPSUL solution enables optimal process performance for production of premier quality PCL grades at competitive rates
The product has been in-licensed from Strides and will be commercialized by Amneal
The company also organised sensitization workshops for its employees aimed at increasing awareness of challenges faced by hearing-impaired individuals
A new GSK survey shows a large number of adults do not understand how shingles may be triggered
Subscribe To Our Newsletter & Stay Updated
